KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Liabilities and Shareholders Equity Long-Term Investments Minority Interest Non-Current Assets Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Accured Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Vir Biotechnology (VIR) Preferred Stock Liabilities (2018 - 2019)

Vir Biotechnology's Preferred Stock Liabilities history spans 2 years, with the latest figure at $636.6 million for Q3 2019.

On a quarterly basis, Preferred Stock Liabilities rose 105.93% to $636.6 million in Q3 2019 year-over-year; TTM through Sep 2019 was $636.6 million, a 105.93% increase, with the full-year FY2018 number at $309.1 million, up 5.68% from a year prior.
Preferred Stock Liabilities hit $636.6 million in Q3 2019 for Vir Biotechnology, roughly flat from $636.6 million in the prior quarter.
Over the last five years, Preferred Stock Liabilities for VIR hit a ceiling of $636.6 million in Q2 2019 and a floor of $307.2 million in Q2 2018.